Inhibitory effect of fluvastatin on lysophosphatidylcholine-induced ventricular arrhythmias in rats.
- Author:
Li-Bing LI
1
;
Hong-Ye WANG
;
Lan MA
;
Chang-Qing GAO
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Arrhythmias, Cardiac; chemically induced; metabolism; Drug Antagonism; Fatty Acids, Monounsaturated; pharmacology; Indoles; pharmacology; Ion Channels; drug effects; Lysophosphatidylcholines; adverse effects; Male; Myocytes, Cardiac; metabolism; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; metabolism
- From: Journal of Southern Medical University 2011;31(4):578-581
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of fluvastatin on lysophosphatidylcholine (LPC)-induced ventricular arrhythmias and its mechanism.
METHODSTwenty male SD rats were randomly allocated into two equal groups, namely LPC treatment group and fluvastatin pretreatment group. Langendorff apparatus was used for cardiac perfusion ex vivo with 5 µmol/L LPC for 5 min followed by washing for 30 min in LPC treatment group, and in fluvastatin pretreatment group, a 30-min perfusion with 10 µmol/L fluvastatin was administered before LPC perfusion. The LPC-induced nonselective cation current (I(NSC)) in the ventricular myocytes was recorded using the whole-cell voltage-clamp method.
RESULTSFluvastatin significantly inhibited LPC-induced ventricular tachyarrhythmia/fibrillation and I(NSC). The small G-protein Rho inhibitor (C3) and Rho-kinase inhibitor (Y-27632) in the pipette solution also suppressed LPC-induced I(NSC).
CONCLUSIONFluvastatin offers cardiac protection against LPC by inhibiting LPC-induced I(NSC). LPC induces fatal arrhythmia via a Rho/Rho-kinase-mediated pathway.
